Medical Therapy Induced Regression of Plaque in a Female Patient with ASCVD

Int Heart J. 2019 Jan 25;60(1):175-177. doi: 10.1536/ihj.17-394. Epub 2018 Nov 20.

Abstract

The initiation and progression of atherosclerotic cardiovascular disease (ASCVD) has always been associated with a series of risk factors. Evidences of statin therapy from randomized clinical trials are abundant, whereas discussions regarding patients with ASCVD without evidence-based risk factors are rare. Here, we describe a case of a 58-year-old woman who was diagnosed with ASCVD with none of these evidence-based risk factors. After four years of medical interventions, including atorvastatin, the patient recovered completely from severe chest pain with significant regression of atherosclerotic plaques in coronary arteries.

Keywords: Atorvastatin.

Publication types

  • Case Reports

MeSH terms

  • Atorvastatin / administration & dosage
  • Atorvastatin / therapeutic use
  • Cardiovascular Diseases / drug therapy*
  • Cardiovascular Diseases / pathology
  • Computed Tomography Angiography / methods
  • Coronary Artery Disease / diagnosis
  • Coronary Artery Disease / drug therapy*
  • Coronary Vessels / diagnostic imaging
  • Coronary Vessels / pathology
  • Female
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
  • Middle Aged
  • Plaque, Atherosclerotic / drug therapy*
  • Randomized Controlled Trials as Topic
  • Risk Factors
  • Treatment Outcome

Substances

  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Atorvastatin